SCHEMBL1631930

SCHEMBL1631930

Cc1c(O)cccc1[C]=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.50
ATM Q13315 1/20 0.50
CYP3A4 P08684 4/20 0.40
THRB P10828 1/20 0.38
CA2 P00918 6/20 0.36
CA1 P00915 5/20 0.36
CA12 O43570 5/20 0.36
CA14 Q9ULX7 5/20 0.36
CA7 P43166 4/20 0.36
CA9 Q16790 4/20 0.36
ALDH1A1 P00352 5/20 0.36
HSD17B10 Q99714 5/20 0.36
LMNA P02545 4/20 0.36
HPGD P15428 4/20 0.36
ALOX15 P16050 4/20 0.36
RECQL P46063 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
EGFR P00533 2/20 0.36
FYN P06241 2/20 0.36
MMP9 P14780 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809871 0.77 TRPA1 (0.50) TRPA1ATMCYP3A4THRBCA2
SCHEMBL29451048 0.77 TRPA1 (0.50) TRPA1ATMCA2CA1ALDH1A1
SCHEMBL16954573 0.77 TRPA1 (0.50) TRPA1ATMCYP3A4THRBCA2
SCHEMBL2137032 0.77 TRPA1 (0.50) TRPA1ATMCA2CA1ALDH1A1
SCHEMBL874656 0.76 ALDH1A1 (0.52) TRPA1CYP3A4THRBCA2CA1
SCHEMBL28057552 0.76 TRPA1 (0.54) TRPA1ATMCYP3A4THRBCA2
SCHEMBL1312250 0.76 CYP3A4 (0.43) TRPA1ATMCYP3A4CA2CA1
SCHEMBL2813183 0.76 TRPA1 (0.48) TRPA1ATMCYP3A4THRBCA2
SCHEMBL671168 0.75
SCHEMBL335267 0.74 CA2 (0.38) TRPA1ATMCYP3A4THRBCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932264-B2 Sinomenine derivatives and preparation and uses thereof NATUREMED GROUP CORPORATION (US) 2011-04-26 US claimed
CN-100439331-C Intermediate of anti-AIDS medicine 'Nelfinavir' and its syntesizing process and application SHANGHAI INST ORGANIC CHEM (CN) 2008-12-03 CN claimed
CN-1390831-A Intermediate of anti-AIDS medicine 'Nelfinavir' and its syntesizing process and application SHANGHAI INST ORGANIC CHEM (CN) 2003-01-15 CN claimed
CN-1132756-A Antiviral ethers of aspartate protease substrate isosteres CIBA GEIGY AG (CH) 1996-10-09 CN claimed
EP-0708085-A2 Antiviral ethers of aspartate protease substrate isosteres CIBA-GEIGY AG (CH) 1996-04-24 EP claimed
CN-102711720-A Pigmentation preventing or improving agent POLA CHEM IND INC 2012-10-03 CN disclosed
CN-100439331-C Intermediate of anti-AIDS medicine 'Nelfinavir' and its syntesizing process and application SHANGHAI INST ORGANIC CHEM (CN) 2008-12-03 CN disclosed
CN-100439331-C Intermediate of anti-AIDS medicine 'Nelfinavir' and its syntesizing process and application SHANGHAI INST ORGANIC CHEM (CN) 2008-12-03 CN disclosed
US-7217794-B2 Compounds and methods for treatment of thrombosis DAIAMED, INC. (US) 2007-05-15 US disclosed
US-20050215801-A1 Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates KANEKA CORPORATION (JP) 2005-09-29 US disclosed
EP-1553093-A1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES KANEKA CORPORATION (JP) 2005-07-13 EP disclosed
US-20050143317-A1 Compounds and methods for treatment of thrombosis EXITHERA PHARMACEUTICALS LLC 2005-06-30 US disclosed
EP-0972760-A1 PROCESS FOR THE PURIFICATION OR ISOLATION OF (2S, 3R)-1-HALO-2-HYDROXY-3-(PROTECTED AMINO)-4-PHENYLTHIOBUTANES OR OPTICAL ANTIPODES THEREOF KANEKA CORPORATION (JP) 2000-01-19 EP disclosed
EP-0969000-A1 PROCESS FOR REDUCING $G(a)-AMINO KETONES KANEKA CORPORATION (JP) 2000-01-05 EP disclosed
CN-1228081-A Process for reducing alpha-aminoketones KANEKA CORP (JP) 1999-09-08 CN disclosed
US-5935976-A Antiviral ethers of aspartate protease substrate isosteres NOVARTIS CORPORATION (US) 1999-08-10 US disclosed
US-5807891-A RETROVIRUSES NOVARTIS AG (CH) 1998-09-15 US disclosed
US-5663200-A CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES CIBA-GEIGY CORPORATION (US) 1997-09-02 US disclosed
CN-1132756-A Antiviral ethers of aspartate protease substrate isosteres CIBA GEIGY AG (CH) 1996-10-09 CN disclosed
EP-0708085-A2 Antiviral ethers of aspartate protease substrate isosteres CIBA-GEIGY AG (CH) 1996-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143317-A1 Compounds and methods for treatment of thrombosis SERPINC1, F11, F13B TRPA1 4684/4885ATM 2618/4885CYP3A4 964/4885
US-20050215801-A1 Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates OXER1, RCC2, CBR3 TRPA1 257/4885ATM 1892/4885CYP3A4 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.